Capivasertib (AZD5363, Truqap) competitively interacts with the ATP binding site of all three AKT isoforms (AKT1/2/3) and inhibits AKT’s catalytic activity with high potency and higher selectivity than previously developed compounds, resulting in the arrest of tumor cell growth (4). This evidence concerns the gene AKT1 and neoplasm.